METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
批准号:
2856200
负责人:
JOHN H GALIVAN
金额:
$18.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1979
资助国家:
美国
项目状态:
已结题
起止时间:
1979-07-01 至 2000-12-31
关键词:
antibody complementary DNA drug metabolism drug resistance electron microscopy enzyme activity folate antagonist gene expression glutaminase glycoprotein structure hydrolase insulin intracellular transport laboratory rat liver cells lysosomes methotrexate neoplasm /cancer pharmacology polyglutamates site directed mutagenesis tissue /cell culture
中文摘要
抗叶酸剂的聚谷氨酸衍生物已经被确定为
这类抗肿瘤药物治疗效率的主要决定因素是
剂. 这些衍生物的形成已经在一个
转化细胞系的数量和分离的叶酸聚谷氨酸盐
合成酶 相反,这些γ-谷氨酰的裂解过程
尚未对衍生工具进行足够深入或详细的评估。 的
本研究的重点是催化这一过程的酶,γ-谷氨酰
水解酶(GH)。 上一个赠款期的研究建立了一个
关于这种酶的一些特征:1)它是一种糖蛋白(Mr-55 kDa)
具有33 kDa的肽Mr,2)它主要是分泌酶(在所有
测试的肿瘤细胞),其主要细胞位置是溶酶体,3)和
其活性细胞内升高是获得性药物的机制
(4)它的提升对减少
细胞抗叶酸剂多聚谷氨酸盐,而不是叶酸酰多聚谷氨酸盐,和5)cDNA
已克隆并鉴定了大鼠肝癌生长激素的基因,
推导的氨基酸序列建立。 GH的详细评估将
以确定其在抗叶酸剂药理学中的作用
包括1)进一步研究GH基因及其表达的影响因素,
,
2)使用定点诱变和详细的物理和
生化分析,以了解糖蛋白的结构,
作用机制,3)确定酶的改变机制
获得性耐药性和对胰岛素和其他
组织培养条件的扰动,4)评估细胞定位
n
用多克隆抗体通过显微镜观察GH,并研究其
细胞运输,以及5)使用分子方法来增强或
抑制细胞中的GH水平,并根据效果评估结果
抗叶酸活性和多聚谷氨酰化,GH功能和叶酸生长
依赖 将进行这些调查,以确定GH是否可以
被利用为目标,或者对其功能的修改是否可以利用
艾德
以增强抗叶酸剂的治疗选择性。 最后
GH的分泌将被详细检查,以了解其
生物学和药理学意义,并开发工具,
确定其作为诊断标志物的潜力。
英文摘要
The polyglutamate derivatives of antifolates have been established as being
a major determinant in the therapeutic efficiency of this class of antitumo
agents. The formation of these derivatives has been characterized in a
number of transformed cell lines and with isolated folypolyglutamate
synthetase. In contrast, the process of cleavage of these y-glutamyl
derivatives has not yet been evaluated in sufficient depth or detail. The
focus of this study is the enzyme that catalyzes this process, y-glutamyl
hydrolase (GH). Studies in the previous grant period have established a
number of features about this enzyme: 1) it is a glycoprotein (Mr-55 kDa)
with a peptide Mr of 33kDa, 2) it is primarily a secreted enzyme (in all
tumor cells tested) whose primary cellular location is the lysosome, 3) an
intracellular elevation in its activity is a mechanism of acquired drug
resistance, 4) its elevation has a more profound effect in diminishing
cellular antifolate polyglutamates than folyl polyglutamates, and 5) a cDNA
for GH from rat hepatoma has been cloned and characterized and the
deduced amino acid sequence established. A detailed evaluation of GH will
be made in order to establish its role in the pharmacology of the antifolat
including 1) further studies on GH gene and factors that alter its expressi
,
2) the use of site directed mutagenesis and detailed physical and
biochemical analysis to understand the structure of the glycoprotein and it
mechanism of action, 3) determining the mechanism of alteration in enzyme
activity in acquired drug resistance and in response to insulin and other
perturbations in tissue culture conditions, 4) evaluating the cytolocalizat
n
of GH by microscopy using polyclonal antibodies and investigating its
cellular trafficking, and 5) using molecular methodology to enhance or
inhibit GH levels in cells and evaluate the outcome in terms of the effect
antifolate activity and polyglutamylation, GH function and folate growth
dependence. These investigations will be conducted to determine if GH can
be exploited as a target or if the modification of its function can be util
ed
to enhance the therapeutic selectivity of the antifolates. Lastly, the
secretion of GH will be examined in detail in order to understand its
biological and pharmacological significance and to develop the tools to
determine its potential as a diagnostic marker.
期刊论文(45)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1021/jm00126a023
发表时间:
1989
期刊:
Journal of medicinal chemistry
影响因子:
7.3
作者:
[Patil,SD, Jones,C, Nair,MG, Galivan,J, Maley,F, Kisliuk,RL, Gaumont,Y, Duch,D, Ferone,R]
通讯作者:
Ferone,R
Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
体外暴露于 N10-propargyl-5,8-dideazafolate 与甲氨蝶呤或亲脂性抗叶酸剂三甲曲沙或美托品对大鼠肝癌细胞的协同生长抑制作用。
DOI:
--
发表时间:
1987
期刊:
Cancer research
影响因子:
11.2
作者:
[Galivan,J, Nimec,Z, Rhee,M]
通讯作者:
Rhee,M
Prevention of colchicine toxicity to cultured rat hepatocytes by glucagon, hydrocortisone and insulin.
胰高血糖素、氢化可的松和胰岛素预防秋水仙碱对培养大鼠肝细胞的毒性。
DOI:
10.1016/0014-4827(81)90241-x
发表时间:
1981
期刊:
Experimental cell research
影响因子:
3.7
作者:
[Galivan,J]
通讯作者:
Galivan,J
Effects of gamma-glutamyl hydrolase on folyl and antifolylpolyglutamates in cultured H35 hepatoma cells.
γ-谷氨酰水解酶对培养的 H35 肝癌细胞中叶酰和抗叶酰聚谷氨酸的影响。
DOI:
--
发表时间:
1995
期刊:
Molecular pharmacology.
影响因子:
--
作者:
[Yao,R, Rhee,MS, Galivan,J]
通讯作者:
Galivan,J
The absence of gamma-glutamyltransferase activity in transport-dependent methotrexate-resistant hepatoma cells.
运输依赖性甲氨蝶呤耐药肝癌细胞中缺乏γ-谷氨酰转移酶活性。
DOI:
10.1002/ijc.2910400622
发表时间:
1987
期刊:
International journal of cancer
影响因子:
6.4
作者:
[Kruger-McDermott,C, Johnson,TB, Rej,R, vanderHoeven,T, Nair,MG, Galivan,J]
通讯作者:
Galivan,J
共 40 条
WADSWORTH CTR: INFECTIOUS DIS, WEST NILE, AIDS, MALARIA, TB, BIOTERRORISM, LYME
-
批准号:6794518
-
项目类别:
-
资助金额:$199.93万
-
财政年份:2002
-
负责人:JOHN H GALIVAN
-
依托单位:
DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
-
批准号:3189422
-
项目类别:
-
资助金额:$8.26万
-
财政年份:1988
-
负责人:JOHN H GALIVAN
-
依托单位:
DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
-
批准号:3189421
-
项目类别:
-
资助金额:$8.01万
-
财政年份:1988
-
负责人:JOHN H GALIVAN
-
依托单位:
DRUG SYNERGY WITH ANTIFOLATE COMBINATIONS
-
批准号:3189420
-
项目类别:
-
资助金额:$7.99万
-
财政年份:1988
-
负责人:JOHN H GALIVAN
-
依托单位:
VITAMIN FUNCTION IN LIVER STUDIED IN VITRO
-
批准号:3172035
-
项目类别:
-
资助金额:$11.1万
-
财政年份:1984
-
负责人:JOHN H GALIVAN
-
依托单位:
VITAMIN FUNCTION IN LIVER STUDIED IN VITRO
-
批准号:3172036
-
项目类别:
-
资助金额:$8.74万
-
财政年份:1984
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167079
-
项目类别:
-
资助金额:$21.91万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167077
-
项目类别:
-
资助金额:$11.23万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167073
-
项目类别:
-
资助金额:$6.23万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167076
-
项目类别:
-
资助金额:$10.37万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167072
-
项目类别:
-
资助金额:$18.93万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE AND METABOLISM IN HEPATIC CELLS
-
批准号:2087428
-
项目类别:
-
资助金额:$23.68万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167071
-
项目类别:
-
资助金额:$11.56万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167074
-
项目类别:
-
资助金额:$10.51万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
-
批准号:2633718
-
项目类别:
-
资助金额:$18.35万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE AND METABOLISM IN HEPATIC CELLS
-
批准号:2087429
-
项目类别:
-
资助金额:$24.34万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167078
-
项目类别:
-
资助金额:$20.83万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
-
批准号:3167075
-
项目类别:
-
资助金额:$8.96万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
METHOTREXATE UPTAKE AND METABOLISM IN HEPATIC CELLS
-
批准号:2007274
-
项目类别:
-
资助金额:$17.82万
-
财政年份:1979
-
负责人:JOHN H GALIVAN
-
依托单位:
海外基金